Editorial - (2025) Volume 11, Issue 3
The pharmaceutical industry is undergoing a seismic transformation. Driven by artificial intelligence (AI), digital therapeutics, and evolving regulatory frameworks, drug licensing is no longer confined to traditional pathways. These innovations promise faster approvals, personalized treatments, and broader access—but they also raise new challenges around safety, ethics, and compliance. As we look ahead, the future of drug licensing will be defined by how effectively stakeholders adapt to these emerging trends.
Abstract
The pharmaceutical industry is undergoing a seismic transformation. Driven by artificial intelligence (AI), digital therapeutics, and evolving regulatory frameworks, drug licensing is no longer confined to traditional pathways. These innovations promise faster approvals, personalized treatments, and broader access—but they also raise new challenges around safety, ethics, and compliance. As we look ahead, the future of drug licensing will be defined by how effectively stakeholders adapt to these emerging trends.
Published: 26-Sep-2025, DOI: 10.35248/2471-268X.24.11(3).001
Copyright:This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
